Earnings Call · Q3 FY2024·2024-11-06

Q3 24EPS +43.75%·Rev n/aQ2 24EPS +61.90%·Rev n/aQ1 24EPS -100.00%*·Rev n/aQ4 23EPS +55.56%·Rev n/a⚠ consensus missing

Vanda Pharmaceuticals Inc. VNDA

Kevin Moran — Chief Financial Officer

Mihael Polymeropoulos — Chief Executive Officer

+2.7%1d on move date+1.9% vs SPY3d+9.2%5d+11.7%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VNDA calls or request research access.

More VNDA calls Browse calls Request research access